Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Identifieur interne : 003A67 ( Main/Exploration ); précédent : 003A66; suivant : 003A68Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Auteurs : Suresh S. Ramalingam [États-Unis] ; Pasi A. J Nne [États-Unis] ; Tony Mok [République populaire de Chine] ; Kenneth O'Byrne [Australie] ; Michael J. Boyer [Australie] ; Joachim Von Pawel [Allemagne] ; Adam Pluzanski [Pologne] ; Mikhail Shtivelband [États-Unis] ; Lara Iglesias Docampo [Espagne] ; Jaafar Bennouna [France] ; Hui Zhang [République populaire de Chine] ; Jane Q. Liang [États-Unis] ; Jim P. Doherty [États-Unis] ; Ian Taylor [États-Unis] ; Cecile B. Mather [États-Unis] ; Zelanna Goldberg [États-Unis] ; Joseph O'Connell [États-Unis] ; Luis Paz-Ares [Espagne]Source :
- The Lancet. Oncology [ 1474-5488 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Carcinome pulmonaire non à petites cellules (anatomopathologie), Carcinome pulmonaire non à petites cellules (génétique), Carcinome pulmonaire non à petites cellules (traitement médicamenteux), Chlorhydrate d'erlotinib, Femelle, Humains, Inhibiteurs de protéines kinases (administration et posologie), Mâle, Méthode en double aveugle, Protéines G ras (génétique), Protéines proto-oncogènes (génétique), Protéines proto-oncogènes p21(ras), Quinazolines (administration et posologie), Quinazolinones (administration et posologie), Récepteur du facteur de croissance épidermique (antagonistes et inhibiteurs), Stade de la tumeur, Sujet âgé, Survie sans rechute.
- MESH :
- administration et posologie : Inhibiteurs de protéines kinases, Quinazolines, Quinazolinones.
- anatomopathologie : Carcinome pulmonaire non à petites cellules.
- antagonistes et inhibiteurs : Récepteur du facteur de croissance épidermique.
- génétique : Carcinome pulmonaire non à petites cellules, Protéines G ras, Protéines proto-oncogènes.
- traitement médicamenteux : Carcinome pulmonaire non à petites cellules.
- Adulte, Adulte d'âge moyen, Chlorhydrate d'erlotinib, Femelle, Humains, Mâle, Méthode en double aveugle, Protéines proto-oncogènes p21(ras), Stade de la tumeur, Sujet âgé, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Aged, Carcinoma, Non-Small-Cell Lung (drug therapy), Carcinoma, Non-Small-Cell Lung (genetics), Carcinoma, Non-Small-Cell Lung (pathology), Disease-Free Survival, Double-Blind Method, Erlotinib Hydrochloride, Female, Humans, Male, Middle Aged, Neoplasm Staging, Protein Kinase Inhibitors (administration & dosage), Proto-Oncogene Proteins (genetics), Proto-Oncogene Proteins p21(ras), Quinazolines (administration & dosage), Quinazolinones (administration & dosage), Receptor, Epidermal Growth Factor (antagonists & inhibitors), ras Proteins (genetics).
- MESH :
- chemical , administration & dosage : Protein Kinase Inhibitors, Quinazolines, Quinazolinones.
- chemical , antagonists & inhibitors : Receptor, Epidermal Growth Factor.
- chemical , genetics : Proto-Oncogene Proteins, ras Proteins.
- chemical : Erlotinib Hydrochloride, Proto-Oncogene Proteins p21(ras).
- drug therapy : Carcinoma, Non-Small-Cell Lung.
- genetics : Carcinoma, Non-Small-Cell Lung.
- pathology : Carcinoma, Non-Small-Cell Lung.
- Adult, Aged, Disease-Free Survival, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Staging.
Abstract
Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. We aimed to compare dacomitinib with erlotinib in a phase 3 study.
DOI: 10.1016/S1470-2045(14)70452-8
PubMed: 25439691
Affiliations:
- Allemagne, Australie, Espagne, France, Pologne, République populaire de Chine, États-Unis
- Arizona, Bavière, Californie, Communauté de Madrid, Connecticut, District de Haute-Bavière, Géorgie (États-Unis), Massachusetts, Pays de la Loire, État de New York
- Madrid, Munich, Nantes, Sha Tin
- Université chinoise de Hong Kong
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003324
- to stream PubMed, to step Curation: 003213
- to stream PubMed, to step Checkpoint: 003213
- to stream Ncbi, to step Merge: 002031
- to stream Ncbi, to step Curation: 002031
- to stream Ncbi, to step Checkpoint: 002031
- to stream Main, to step Merge: 003B13
- to stream Main, to step Curation: 003A67
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.</title><author><name sortKey="Ramalingam, Suresh S" sort="Ramalingam, Suresh S" uniqKey="Ramalingam S" first="Suresh S" last="Ramalingam">Suresh S. Ramalingam</name><affiliation wicri:level="2"><nlm:affiliation>Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA. Electronic address: ssramal@emory.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="J Nne, Pasi A" sort="J Nne, Pasi A" uniqKey="J Nne P" first="Pasi A" last="J Nne">Pasi A. J Nne</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name><affiliation wicri:level="4"><nlm:affiliation>State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Woolloongabba, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Woolloongabba, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Boyer, Michael J" sort="Boyer, Michael J" uniqKey="Boyer M" first="Michael J" last="Boyer">Michael J. Boyer</name><affiliation wicri:level="1"><nlm:affiliation>Chris O'Brien Lifehouse/Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Chris O'Brien Lifehouse/Royal Prince Alfred Hospital, Camperdown, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Von Pawel, Joachim" sort="Von Pawel, Joachim" uniqKey="Von Pawel J" first="Joachim" last="Von Pawel">Joachim Von Pawel</name><affiliation wicri:level="3"><nlm:affiliation>Asklepios-Fachkliniken, Munchen-Gauting, Gauting, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Asklepios-Fachkliniken, Munchen-Gauting, Gauting, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Pluzanski, Adam" sort="Pluzanski, Adam" uniqKey="Pluzanski A" first="Adam" last="Pluzanski">Adam Pluzanski</name><affiliation wicri:level="1"><nlm:affiliation>Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Shtivelband, Mikhail" sort="Shtivelband, Mikhail" uniqKey="Shtivelband M" first="Mikhail" last="Shtivelband">Mikhail Shtivelband</name><affiliation wicri:level="2"><nlm:affiliation>Ironwood Cancer and Research Centers, Chandler, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ironwood Cancer and Research Centers, Chandler, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Docampo, Lara Iglesias" sort="Docampo, Lara Iglesias" uniqKey="Docampo L" first="Lara Iglesias" last="Docampo">Lara Iglesias Docampo</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Cancerologie de I'Ouest, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancerologie de I'Ouest, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Zhang, Hui" sort="Zhang, Hui" uniqKey="Zhang H" first="Hui" last="Zhang">Hui Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer (China) Research and Development, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Pfizer (China) Research and Development, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liang, Jane Q" sort="Liang, Jane Q" uniqKey="Liang J" first="Jane Q" last="Liang">Jane Q. Liang</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Doherty, Jim P" sort="Doherty, Jim P" uniqKey="Doherty J" first="Jim P" last="Doherty">Jim P. Doherty</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Taylor, Ian" sort="Taylor, Ian" uniqKey="Taylor I" first="Ian" last="Taylor">Ian Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mather, Cecile B" sort="Mather, Cecile B" uniqKey="Mather C" first="Cecile B" last="Mather">Cecile B. Mather</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Goldberg, Zelanna" sort="Goldberg, Zelanna" uniqKey="Goldberg Z" first="Zelanna" last="Goldberg">Zelanna Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Connell, Joseph" sort="O Connell, Joseph" uniqKey="O Connell J" first="Joseph" last="O'Connell">Joseph O'Connell</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25439691</idno><idno type="pmid">25439691</idno><idno type="doi">10.1016/S1470-2045(14)70452-8</idno><idno type="wicri:Area/PubMed/Corpus">003324</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003324</idno><idno type="wicri:Area/PubMed/Curation">003213</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003213</idno><idno type="wicri:Area/PubMed/Checkpoint">003213</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003213</idno><idno type="wicri:Area/Ncbi/Merge">002031</idno><idno type="wicri:Area/Ncbi/Curation">002031</idno><idno type="wicri:Area/Ncbi/Checkpoint">002031</idno><idno type="wicri:Area/Main/Merge">003B13</idno><idno type="wicri:Area/Main/Curation">003A67</idno><idno type="wicri:Area/Main/Exploration">003A67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.</title><author><name sortKey="Ramalingam, Suresh S" sort="Ramalingam, Suresh S" uniqKey="Ramalingam S" first="Suresh S" last="Ramalingam">Suresh S. Ramalingam</name><affiliation wicri:level="2"><nlm:affiliation>Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA. Electronic address: ssramal@emory.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="J Nne, Pasi A" sort="J Nne, Pasi A" uniqKey="J Nne P" first="Pasi A" last="J Nne">Pasi A. J Nne</name><affiliation wicri:level="2"><nlm:affiliation>Dana-Farber Cancer Institute, Boston, MA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Dana-Farber Cancer Institute, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name><affiliation wicri:level="4"><nlm:affiliation>State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong</wicri:regionArea><orgName type="university">Université chinoise de Hong Kong</orgName><placeName><settlement type="city">Sha Tin</settlement></placeName></affiliation></author><author><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name><affiliation wicri:level="1"><nlm:affiliation>Princess Alexandra Hospital, Woolloongabba, QLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Princess Alexandra Hospital, Woolloongabba, QLD</wicri:regionArea><wicri:noRegion>QLD</wicri:noRegion></affiliation></author><author><name sortKey="Boyer, Michael J" sort="Boyer, Michael J" uniqKey="Boyer M" first="Michael J" last="Boyer">Michael J. Boyer</name><affiliation wicri:level="1"><nlm:affiliation>Chris O'Brien Lifehouse/Royal Prince Alfred Hospital, Camperdown, Sydney, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Chris O'Brien Lifehouse/Royal Prince Alfred Hospital, Camperdown, Sydney, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Von Pawel, Joachim" sort="Von Pawel, Joachim" uniqKey="Von Pawel J" first="Joachim" last="Von Pawel">Joachim Von Pawel</name><affiliation wicri:level="3"><nlm:affiliation>Asklepios-Fachkliniken, Munchen-Gauting, Gauting, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Asklepios-Fachkliniken, Munchen-Gauting, Gauting, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Pluzanski, Adam" sort="Pluzanski, Adam" uniqKey="Pluzanski A" first="Adam" last="Pluzanski">Adam Pluzanski</name><affiliation wicri:level="1"><nlm:affiliation>Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.</nlm:affiliation><country xml:lang="fr">Pologne</country><wicri:regionArea>Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw</wicri:regionArea><wicri:noRegion>Warsaw</wicri:noRegion></affiliation></author><author><name sortKey="Shtivelband, Mikhail" sort="Shtivelband, Mikhail" uniqKey="Shtivelband M" first="Mikhail" last="Shtivelband">Mikhail Shtivelband</name><affiliation wicri:level="2"><nlm:affiliation>Ironwood Cancer and Research Centers, Chandler, AZ, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Ironwood Cancer and Research Centers, Chandler, AZ</wicri:regionArea><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Docampo, Lara Iglesias" sort="Docampo, Lara Iglesias" uniqKey="Docampo L" first="Lara Iglesias" last="Docampo">Lara Iglesias Docampo</name><affiliation wicri:level="3"><nlm:affiliation>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid</wicri:regionArea><placeName><settlement type="city">Madrid</settlement><region nuts="2" type="region">Communauté de Madrid</region></placeName></affiliation></author><author><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name><affiliation wicri:level="3"><nlm:affiliation>Institut de Cancerologie de I'Ouest, Nantes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut de Cancerologie de I'Ouest, Nantes</wicri:regionArea><placeName><region type="region">Pays de la Loire</region><region type="old region">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name sortKey="Zhang, Hui" sort="Zhang, Hui" uniqKey="Zhang H" first="Hui" last="Zhang">Hui Zhang</name><affiliation wicri:level="1"><nlm:affiliation>Pfizer (China) Research and Development, Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Pfizer (China) Research and Development, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Liang, Jane Q" sort="Liang, Jane Q" uniqKey="Liang J" first="Jane Q" last="Liang">Jane Q. Liang</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Doherty, Jim P" sort="Doherty, Jim P" uniqKey="Doherty J" first="Jim P" last="Doherty">Jim P. Doherty</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Taylor, Ian" sort="Taylor, Ian" uniqKey="Taylor I" first="Ian" last="Taylor">Ian Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Mather, Cecile B" sort="Mather, Cecile B" uniqKey="Mather C" first="Cecile B" last="Mather">Cecile B. Mather</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, Groton, CT, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, Groton, CT</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author><author><name sortKey="Goldberg, Zelanna" sort="Goldberg, Zelanna" uniqKey="Goldberg Z" first="Zelanna" last="Goldberg">Zelanna Goldberg</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, San Diego, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, San Diego, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Connell, Joseph" sort="O Connell, Joseph" uniqKey="O Connell J" first="Joseph" last="O'Connell">Joseph O'Connell</name><affiliation wicri:level="2"><nlm:affiliation>Pfizer Oncology, New York, NY, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Pfizer Oncology, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name><affiliation wicri:level="1"><nlm:affiliation>University Hospital Virgen del Rocio, Seville, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>University Hospital Virgen del Rocio, Seville</wicri:regionArea><wicri:noRegion>Seville</wicri:noRegion></affiliation></author></analytic><series><title level="j">The Lancet. Oncology</title><idno type="eISSN">1474-5488</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Carcinoma, Non-Small-Cell Lung (drug therapy)</term><term>Carcinoma, Non-Small-Cell Lung (genetics)</term><term>Carcinoma, Non-Small-Cell Lung (pathology)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Erlotinib Hydrochloride</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Protein Kinase Inhibitors (administration & dosage)</term><term>Proto-Oncogene Proteins (genetics)</term><term>Proto-Oncogene Proteins p21(ras)</term><term>Quinazolines (administration & dosage)</term><term>Quinazolinones (administration & dosage)</term><term>Receptor, Epidermal Growth Factor (antagonists & inhibitors)</term><term>ras Proteins (genetics)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Carcinome pulmonaire non à petites cellules (anatomopathologie)</term><term>Carcinome pulmonaire non à petites cellules (génétique)</term><term>Carcinome pulmonaire non à petites cellules (traitement médicamenteux)</term><term>Chlorhydrate d'erlotinib</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (administration et posologie)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Protéines G ras (génétique)</term><term>Protéines proto-oncogènes (génétique)</term><term>Protéines proto-oncogènes p21(ras)</term><term>Quinazolines (administration et posologie)</term><term>Quinazolinones (administration et posologie)</term><term>Récepteur du facteur de croissance épidermique (antagonistes et inhibiteurs)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie sans rechute</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Protein Kinase Inhibitors</term><term>Quinazolines</term><term>Quinazolinones</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptor, Epidermal Growth Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Proto-Oncogene Proteins</term><term>ras Proteins</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Erlotinib Hydrochloride</term><term>Proto-Oncogene Proteins p21(ras)</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Quinazolines</term><term>Quinazolinones</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteur du facteur de croissance épidermique</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term><term>Protéines G ras</term><term>Protéines proto-oncogènes</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma, Non-Small-Cell Lung</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Carcinome pulmonaire non à petites cellules</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Chlorhydrate d'erlotinib</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Protéines proto-oncogènes p21(ras)</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor. Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for dacomitinib compared with erlotinib. We aimed to compare dacomitinib with erlotinib in a phase 3 study.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Espagne</li><li>France</li><li>Pologne</li><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Arizona</li><li>Bavière</li><li>Californie</li><li>Communauté de Madrid</li><li>Connecticut</li><li>District de Haute-Bavière</li><li>Géorgie (États-Unis)</li><li>Massachusetts</li><li>Pays de la Loire</li><li>État de New York</li></region><settlement><li>Madrid</li><li>Munich</li><li>Nantes</li><li>Sha Tin</li></settlement><orgName><li>Université chinoise de Hong Kong</li></orgName></list><tree><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Ramalingam, Suresh S" sort="Ramalingam, Suresh S" uniqKey="Ramalingam S" first="Suresh S" last="Ramalingam">Suresh S. Ramalingam</name></region><name sortKey="Doherty, Jim P" sort="Doherty, Jim P" uniqKey="Doherty J" first="Jim P" last="Doherty">Jim P. Doherty</name><name sortKey="Goldberg, Zelanna" sort="Goldberg, Zelanna" uniqKey="Goldberg Z" first="Zelanna" last="Goldberg">Zelanna Goldberg</name><name sortKey="J Nne, Pasi A" sort="J Nne, Pasi A" uniqKey="J Nne P" first="Pasi A" last="J Nne">Pasi A. J Nne</name><name sortKey="Liang, Jane Q" sort="Liang, Jane Q" uniqKey="Liang J" first="Jane Q" last="Liang">Jane Q. Liang</name><name sortKey="Mather, Cecile B" sort="Mather, Cecile B" uniqKey="Mather C" first="Cecile B" last="Mather">Cecile B. Mather</name><name sortKey="O Connell, Joseph" sort="O Connell, Joseph" uniqKey="O Connell J" first="Joseph" last="O'Connell">Joseph O'Connell</name><name sortKey="Shtivelband, Mikhail" sort="Shtivelband, Mikhail" uniqKey="Shtivelband M" first="Mikhail" last="Shtivelband">Mikhail Shtivelband</name><name sortKey="Taylor, Ian" sort="Taylor, Ian" uniqKey="Taylor I" first="Ian" last="Taylor">Ian Taylor</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Mok, Tony" sort="Mok, Tony" uniqKey="Mok T" first="Tony" last="Mok">Tony Mok</name></noRegion><name sortKey="Zhang, Hui" sort="Zhang, Hui" uniqKey="Zhang H" first="Hui" last="Zhang">Hui Zhang</name></country><country name="Australie"><noRegion><name sortKey="O Byrne, Kenneth" sort="O Byrne, Kenneth" uniqKey="O Byrne K" first="Kenneth" last="O'Byrne">Kenneth O'Byrne</name></noRegion><name sortKey="Boyer, Michael J" sort="Boyer, Michael J" uniqKey="Boyer M" first="Michael J" last="Boyer">Michael J. Boyer</name></country><country name="Allemagne"><region name="Bavière"><name sortKey="Von Pawel, Joachim" sort="Von Pawel, Joachim" uniqKey="Von Pawel J" first="Joachim" last="Von Pawel">Joachim Von Pawel</name></region></country><country name="Pologne"><noRegion><name sortKey="Pluzanski, Adam" sort="Pluzanski, Adam" uniqKey="Pluzanski A" first="Adam" last="Pluzanski">Adam Pluzanski</name></noRegion></country><country name="Espagne"><region name="Communauté de Madrid"><name sortKey="Docampo, Lara Iglesias" sort="Docampo, Lara Iglesias" uniqKey="Docampo L" first="Lara Iglesias" last="Docampo">Lara Iglesias Docampo</name></region><name sortKey="Paz Ares, Luis" sort="Paz Ares, Luis" uniqKey="Paz Ares L" first="Luis" last="Paz-Ares">Luis Paz-Ares</name></country><country name="France"><region name="Pays de la Loire"><name sortKey="Bennouna, Jaafar" sort="Bennouna, Jaafar" uniqKey="Bennouna J" first="Jaafar" last="Bennouna">Jaafar Bennouna</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25439691
|texte= Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25439691" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |